干扰素α-2b联合阿德福韦酯治疗慢性乙型肝炎疗效观察

Efficacy of interferon α-2b and adefovir dipivoxil combination therapy on chronic hepatitis B

目的探讨干扰素(IFN)α-2b联合阿德福韦酯(ADV)治疗慢性乙型肝炎(chronic hepatitis B,CHB)患者的疗效。方法 47例CHB患者随机分为2组,IFNα-2b联合ADV组(联合用药组)22例,单用ADV组(单药组)25例。监测2组患者治疗12、24、48、96周的HBV DNA水平、HBV血清标志物及ALT变化。结果治疗48周时,联合用药组患者血清中HBV DNA转阴率和ALT复常率明显高于单药组,联合用药组在停用IFNα-2b48周后上述指标仍高于单药组。治疗48周时,联合用药组完全应答率为59%,高于单药组的28%(P<0.05)。结论IFNα-2b联合ADV治疗CHB优于单用ADV,可提高HBeAg/抗HBe血清学转换率及完全应答率。

Objective To investigate the efficacy of interferon （IFN） α-2b and adefovir dipivoxil （ADV） combination therapy on chronic hepatitis B （CHB）. Methods Totally 47 CHB patients were randomly divided into two groups. Twenty-two cases received IFN α-2b and ADV combination treatment （combination therapy group）, and 25 cases ADV alone （monotherapy group）. HBV DNA levels, serum markers and ALT levels were monitored at week 12, 24, 48 and 96 of treatment. Results The patients in combination therapy group had significantly higher HBV DNA negative rate and ALT normalization rate than those in monotherapy group at week 48 of treatment and at week 48 after IFN α-2b withdrawal as well. Complete response was achieved in 59% of the patients in combination therapy group, significantly higher than that in monotherapy group （28%） at week 48 of treatment （P〈0.05）. Conclusions IFN α-2b and ADV combination therapy has better efficacy on CHB patients than ADV monotherapy. Combination therapy can improve the HBeAg seroconversion and complete response.